Fulgent Genetics Inc (FLGT)

92.25 +0.33  +0.36% NASDAQ Jul 30, 20:00 USD

Fulgent Genetics Revenue (TTM):

773.39M for March 31, 2021
View 4,000+ financial data types
View Full Chart

Revenue (TTM) Chart

Export Data
Save Image
Print Image

Historical Revenue (TTM) Data

View and export this data going back to 2016. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2021 773.39M
Dec. 31, 2020 421.71M
Sept. 30, 2020 135.12M
June 30, 2020 43.75M
March 31, 2020 34.91M
Dec. 31, 2019 32.53M
Sept. 30, 2019 29.81M
June 30, 2019 25.09M
March 31, 2019 22.07M
Dec. 31, 2018 21.35M
Sept. 30, 2018 19.96M
June 30, 2018 18.84M
March 31, 2018 18.08M
Dec. 31, 2017 18.73M
Sept. 30, 2017 20.30M
June 30, 2017 20.81M
March 31, 2017 20.14M
Dec. 31, 2016 18.28M
Sept. 30, 2016 15.32M
June 30, 2016 13.22M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.


Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Benchmarks

Senseonics Holdings Inc 7.759M
Illumina Inc 3.473B
Quest Diagnostics Inc 11.06B

Revenue (TTM) Range, Past 5 Years

Minimum 15.32M Sep 2016
Maximum 773.39M Mar 2021
Average 90.01M


Top Growth Stocks for July 2021
Yahoo 06/28 13:25 ET



Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.